Dartmouth-Hitchcock Clinic

Dartmouth-Hitchcock Clinic, doing business as Dartmouth-Hitchcock Obligated Group, is a non-profit academic medical center based in Lebanon, New Hampshire, that functions primarily as a federal grant recipient conducting biomedical and clinical research across the National Institutes of Health and other health agencies. The organization receives the vast majority of its federal funding through research grants rather than service contracts, with 64% of recent awards (212 of 331) arriving as sub-awards from universities and research institutions serving as prime grant recipients.

The clinic's federal footprint centers on NIH-funded research spanning cancer biology, infectious disease, gastroenterology, mental health, pediatric health outcomes, and rural healthcare delivery science. Recent prime contract awards include a $230,000 sole-source purchase order from Veterans Integrated Service Network 1 for deep brain stimulation research in PTSD and traumatic brain injury (September 2025), an $85,000 order for VA radiation oncology data collection (September 2025), a $1.05 million fMRI imaging services definitive contract from VISN 1 (September 2022), and a $90,000 Consumer Product Safety Commission order for consumer product injury data collection (September 2024). These contracts reflect the clinic's capacity to deliver specialized neuroimaging, clinical research support, and data collection services to federal healthcare and safety agencies, performed without set-aside designations and awarded on sole-source or competitive basis.

The clinic's primary customer concentration sits with the National Institutes of Health. The top five NIH institutes and agencies account for 48% of recent awards: the National Cancer Institute (60 awards), the National Institute of Diabetes and Digestive and Kidney Diseases (43 awards), the National Institute of General Medical Sciences (21 awards), the National Institute on Drug Abuse (19 awards), and the Agency for Healthcare Research and Quality (16 awards). The clinic also engages the Defense Health Agency on military medical research and development grants addressing multiple sclerosis telehealth, breast cancer tumor microenvironment targeting, brain tumor survivor support, and epilepsy self-management. The Department of Veterans Affairs represents a smaller but focused customer set, with five awards totaling $1.7 million in combined potential value centered on PTSD research, traumatic brain injury biomarkers, and oncology service development at the White River Junction VA Healthcare System in Vermont.

Award activity has grown substantially. The clinic received four prime and sub-awards combined in 2022, growing to 38 in 2023 and 102 in 2024, with 78 awards in 2025 and 13 through mid-2026. The organization's award portfolio reflects a shift from federal service contracts (which generated $105 thousand in SCI-reported invoicing across FY2022–FY2024, representing fewer than 0.2 FTEs annually) to grant-funded research activity. The combined potential value across the full 331-award portfolio stands at $50.6 million, though obligated dollars ($269.7 million) exceed potential value significantly, reflecting the long tail of multi-year grants with front-loaded funding and completion dates extending through 2030. Within the next twenty-four months, 34 awards worth $1.6 million in combined potential value will reach ultimate completion, signaling moderate recompete exposure.

Dartmouth-Hitchcock functions predominantly as a sub-recipient on federal research grants and as a prime on service-based purchase orders and clinical trial contracts. The clinic holds sub-award positions under prime grant recipients including the Trustees of Dartmouth College (which receives substantial NIH funding and subgrants work to the affiliated clinic), New York University, Mount Sinai, Northwestern University, Stanford University, Harvard Medical School, Johns Hopkins University, and a broad network of academic medical centers and research institutes. The Trustees of Dartmouth College appear with exceptional frequency as a prime grantee with Dartmouth-Hitchcock Clinic sub-awards, reflecting the administrative and research partnership between the college's graduate schools and the clinic's medical center operations. Representative sub-award scope includes maternal and child health research on rural labor induction outcomes (Maternal and Child Health Bureau, $1.2 million), cancer care quality and cost analysis (Harvard-based study on health system integration), epilepsy self-management program implementation (cooperative agreement with the National Center for Chronic Disease Prevention and Health Promotion), and multi-site clinical trials in breast cancer therapeutics, cystic fibrosis immunology, and cardiovascular disease outcomes assessment.

On the prime grant side, the clinic has established independent research programs in translational science, rural healthcare delivery, and clinical investigation. The clinic is recipient of a $2.38 million NIGMS Phase I Center of Biomedical Research Excellence (COBRE) grant establishing the Center for Aging with Serious Illness (June 2026), a $2.27 million NCATS K12 training grant for early-career clinical and translational scientists (August 2025), a multi-million-dollar NCATS cooperative agreement to operate the Dartmouth Clinical and Translational Science Institute (SYNERGY) focused on rural healthcare delivery science (July 2024), and multiple Defense Health Agency grants totaling millions for research on telehealth interventions for multiple sclerosis, brain tumor survivors, and epilepsy self-management. The clinic also received major cancer-focused awards from the National Cancer Institute ($796,394 for bile acid immune regulation research; $5.16 million for tumor microenvironment targeting in triple-negative breast cancer; $2.5 million for incisional negative pressure wound therapy trial) and infrastructure support from the National Institute of General Medical Sciences for a rural healthcare delivery science center ($2.2 million COBRE, April 2023).

The clinic's sub-award footprint across prime research contracts is modest but strategically targeted. As a sub-recipient on a Creare LLC contract (November 2025), the clinic provides ultrasound imaging expertise and large animal model studies for development of an automated needle decompression device. As a sub under a university-led breast cancer clinical trial (MGH Institute of Health Professions, July 2026), the clinic provides fidelity monitoring, site coordination, and participant enrollment support from the Dartmouth Cancer Center. Across prime grant relationships, the clinic typically contributes clinical site operations, patient recruitment and enrollment, data collection and management, and specialized clinical expertise in areas including oncology, neurology, pediatrics, and surgery.

Federal grant work reflects the clinic's positioning as a rural academic medical center anchoring research infrastructure in northern New England. The clinic holds significant awards addressing rural health disparities, aging populations, pediatric behavioral health, maternal health outcomes, chronic disease management in rural settings, and innovation in telehealth and digital health delivery. Performance extends across multi-year cooperative agreements, training and mentorship programs, and pragmatic implementation science focused on translating evidence-based interventions into rural healthcare practice. The clinic leverages institutional partnerships with Dartmouth College (through the Trustees of Dartmouth College Office of Sponsored Projects) and regional healthcare networks (Vermont and New Hampshire primary care and specialty medicine networks) to support research implementation and workforce development.

The organization does not compete under SBA small business set-asides. Prime contracts and grants are awarded without set-aside designation on a competitive or sole-source basis determined by funding agencies. The clinic's federal revenue profile centers on NIH research grants and cooperative agreements (the dominant source), with supplementary funding from the Defense Health Agency (military medical research), the VA (veteran health and PTSD research), the Consumer Product Safety Commission (injury surveillance), and select other HHS agencies (health workforce training, mental health services research). The clinic operates as a non-profit tax-exempt healthcare entity and competes on the basis of clinical research capability, institutional infrastructure, and specialized medical expertise rather than size-based set-asides or minority ownership designations.